Giovanna Masala

Dr. Giovanna Masala

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2018 in Nature
Verified
Journal Article
Open access
PDF file
SASagi Abelson
Sagi Abelson
GCGrace Collord
Grace Collord
SNStanley W. K. Ng
Stanley W. K. Ng
OWOmer Weissbrod
Omer Weissbrod
NCNetta Mendelson Cohen
Netta Mendelson Cohen
LSLiran I. Shlush
Liran I. Shlush
The incidence of acute myeloid leukaemia (AML) increases with age and mortality exceeds 90% when diagnosed after age 65. Most cases arise without any detectable early symptoms and patients usually present with the acute complications of bone marrow failure1. The onset of such de novo AML cases is typically preceded by the accumulation of somatic mutations in preleukaemic haematopoietic stem and progenitor cells (HSPCs) that undergo clonal expansion2,3. However, recurrent AML mutations also accumulate in HSPCs during ageing of healthy individuals who do not develop AML, a phenomenon referred to as age-related clonal haematopoiesis (ARCH)4,5,6,7,8. Here we use deep sequencing to analyse genes that are recurrently mutated in AML to distinguish between individuals who have a high risk of developing AML and those with benign ARCH. We analysed peripheral blood cells from 95 individuals that were obtained on average 6.3 years before AML diagnosis (pre-AML group), together with 414 unselected age- and gender-matched individuals (control group). Pre-AML cases were distinct from controls and had more mutations per sample, higher variant allele frequencies, indicating greater clonal expansion, and showed enrichment of mutations in specific genes. Genetic parameters were used to derive a model that accurately predicted AML-free survival; this model was validated in an independent cohort of 29 pre-AML cases and 262 controls. Because AML is rare, we also developed an AML predictive model using a large electronic health record database that identified individuals at greater risk. Collectively our findings provide proof-of-concept that it is possible to discriminate ARCH from pre-AML many years before malignant transformation. This could in future enable earlier detection and monitoring, and may help to inform intervention.

30 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
NPNikos Papadimitriou
Nikos Papadimitriou
NDNiki Dimou
Niki Dimou
KTKostas Tsilidis
Kostas Tsilidis
BBBarbara Banbury
Barbara Banbury
RMRichard M. Martin
Richard M. Martin
NMNeil Murphy
Neil Murphy
Physical activity has been associated with lower risks of breast and colorectal cancer in epidemiological studies; however, it is unknown if these associations are causal or confounded. In two-sample Mendelian randomisation analyses, using summary genetic data from the UK Biobank and GWA consortia, we found that a one standard deviation increment in average acceleration was associated with lower risks of breast cancer (odds ratio [OR]: 0.51, 95% confidence interval [CI]: 0.27 to 0.98, P-value = 0.04) and colorectal cancer (OR: 0.66, 95% CI: 0.48 to 0.90, P-value = 0.01). We found similar magnitude inverse associations for estrogen positive (ER+ve) breast cancer and for colon cancer. Our results support a potentially causal relationship between higher physical activity levels and lower risks of breast cancer and colorectal cancer. Based on these data, the promotion of physical activity is probably an effective strategy in the primary prevention of these commonly diagnosed cancers.

8 April 2005 in BMJ
Verified
Journal Article
Open access
PDF file
Antonia TricoupoulouAntonia Tricoupoulou
Antonia Tricoupoulou
POPhilippos Orfanos
Philippos Orfanos
TNTeresa Norat
Teresa Norat
BBBas Bueno-De-Mesquita
Bas Bueno-De-Mesquita
MOMarga C Ocké
Marga C Ocké
DTDimitrios Trichopoulos
Dimitrios Trichopoulos
Objective To examine whether adherence to the modified Mediterranean diet, in which unsaturates were substituted for monounsaturates, is associated with longer life expectancy among elderly Europeans. Design Multicentre, prospective cohort study. Setting Nine European countries (Denmark, France, Germany, Greece, Italy, the Netherlands, Spain, Sweden, United Kingdom). Participants 74 607 men and women, aged 60 or more, without coronary heart disease, stroke, or cancer at enrolment and with complete information about dietary intake and potentially confounding variables. Main outcome measures Extent of adherence to a modified Mediterranean diet using a scoring system on a 10 point scale, and death from any cause by time of occurrence, modelled through Cox regression. Results An increase in the modified Mediterranean diet score was associated with lower overall mortality, a two unit increment corresponding to a statistically significant reduction of 8% (95% confidence interval 3% to 12%). No statistically significant evidence of heterogeneity was found among countries in the association of the score with overall mortality even though the association was stronger in Greece and Spain. When dietary exposures were calibrated across countries, the reduction in mortality was 7% (1% to 12%). Conclusion The Mediterranean diet, modified so as to apply across Europe, was associated with increased survival among older people.

3 December 2018 in Nature Genetics
Verified
Journal Article
Open access
JHJeroen R. Huyghe
Jeroen R. Huyghe
SBStephanie A. Bien
Stephanie A. Bien
THTabitha A. Harrison
Tabitha A. Harrison
HKHyun Min Kang
Hyun Min Kang
SCSai Chen
Sai Chen
UPUlrike Peters
Ulrike Peters
To further dissect the genetic architecture of colorectal cancer (CRC), we performed whole-genome sequencing of 1,439 cases and 720 controls, imputed discovered sequence variants and Haplotype Reference Consortium panel variants into genome-wide association study data, and tested for association in 34,869 cases and 29,051 controls. Findings were followed up in an additional 23,262 cases and 38,296 controls. We discovered a strongly protective 0.3% frequency variant signal at CHD1. In a combined meta-analysis of 125,478 individuals, we identified 40 new independent signals at P < 5 × 10-8, bringing the number of known independent signals for CRC to ~100. New signals implicate lower-frequency variants, Krüppel-like factors, Hedgehog signaling, Hippo-YAP signaling, long noncoding RNAs and somatic drivers, and support a role for immune function. Heritability analyses suggest that CRC risk is highly polygenic, and larger, more comprehensive studies enabling rare variant analysis will improve understanding of biology underlying this risk and influence personalized screening strategies and drug development.

1 November 2018 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
TGThe Premenopausal Breast Cancer Collaborative Group
The Premenopausal Breast Cancer Collaborative Group
MSMinouk J. Schoemaker
Minouk J. Schoemaker
HNHazel B. Nichols
Hazel B. Nichols
LWLauren B. Wright
Lauren B. Wright
MBMark N. Brook
Mark N. Brook
ASAnthony J. Swerdlow
Anthony J. Swerdlow
Breast cancer is the most commonly diagnosed cancer among women worldwide, accounting for 25% of female cancer cases at all ages and a greater percentage among young women.1 Its complex etiology involves an unusually large range of factors, of which adiposity, often assessed as body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), is important and appears to have opposing effects at premenopausal and postmenopausal ages.

20 July 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AKAimée R. Kreimer
Aimée R. Kreimer
MJMattias Johansson
Mattias Johansson
TWTim Waterboer
Tim Waterboer
RKRudolf Kaaks
Rudolf Kaaks
JCJenny Chang-Claude
Jenny Chang-Claude
PBPaul Brennan
Paul Brennan
Purpose: Human papillomavirus type 16 (HPV16) infection is causing an increasing number of oropharyngeal cancers in the United States and Europe. The aim of our study was to investigate whether HPV antibodies are associated with head and neck cancer risk when measured in prediagnostic sera. Methods: We identified 638 participants with incident head and neck cancers (patients; 180 oral cancers, 135 oropharynx cancers, and 247 hypopharynx/larynx cancers) and 300 patients with esophageal cancers as well as 1,599 comparable controls from within the European Prospective Investigation Into Cancer and Nutrition cohort. Prediagnostic plasma samples from patients (collected, on average, 6 years before diagnosis) and control participants were analyzed for antibodies against multiple proteins of HPV16 as well as HPV6, HPV11, HPV18, HPV31, HPV33, HPV45, and HPV52. Odds ratios (ORs) of cancer and 95% CIs were calculated, adjusting for potential confounders. All-cause mortality was evaluated among patients using Cox proportional hazards regression. Results: HPV16 E6 seropositivity was present in prediagnostic samples for 34.8% of patients with oropharyngeal cancer and 0.6% of controls (OR, 274; 95% CI, 110 to 681) but was not associated with other cancer sites. The increased risk of oropharyngeal cancer among HPV16 E6 seropositive participants was independent of time between blood collection and diagnosis and was observed more than 10 years before diagnosis. The all-cause mortality ratio among patients with oropharyngeal cancer was 0.30 (95% CI, 0.13 to 0.67), for patients who were HPV16 E6 seropositive compared with seronegative. Conclusion: HPV16 E6 seropositivity was present more than 10 years before diagnosis of oropharyngeal cancers.